BioCryst Pharmaceuticals Inc expected to post a loss of 21 cents a share - Earnings Preview

BioCryst Pharmaceuticals

03/05/2024 16:47

* BioCryst Pharmaceuticals Inc  BCRX.OQ   BCRX.O  is
expected
to show a rise in quarterly revenue when it reports  results on
May 6 for the period ending March 31 2024
    * The Durham North Carolina-based  company is expected to
report a
24.5% increase in revenue to $85.605 million from $68.78 million
a year ago, according to the mean estimate from 10 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for BioCryst Pharmaceuticals
Inc
is for a loss of 21 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for BioCryst
Pharmaceuticals Inc is $11.00​, above​ its last closing price
of $4.48. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.23       -0.24      -0.28     Missed  -14.8
 Sep. 30 2023  -0.24       -0.23      -0.19     Beat    18.6
 Jun. 30 2023  -0.23       -0.23      -0.24     Missed  -5.1​
 Mar. 31 2023  -0.30       -0.30      -0.28     Beat    6.3
 ​​Dec.        -0.13       -0.17      -0.38     Missed  -124.5
 31 2022                                                
 Sep. 30 2022  -0.29       -0.29      -0.23     Beat    20.9​
 Jun. 30 2022  -0.36       -0.34      -0.32     Beat    6.8
 Mar. 31 2022  -0.35       -0.37      -0.40     Missed  -9.2
 This summary was machine generated May 3 at 15:47 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)